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Abstract: Background: Our understanding of mesenchymal cell subsets and their function in human
lung affected by aging and in certain disease settings remain poorly described. Methods: We use a
combination of polychromatic flow cytometry, prospective cell-sorting strategies, confocal imaging, and
modeling of microvessel formation using advanced microfluidic chip technology to characterize mesenchy-
mal cell subtypes in human postnatal and adult lung. Tissue was obtained from patients undergoing
elective surgery for congenital pulmonary airway malformations (CPAM) and other airway abnormalities
including chronic obstructive pulmonary disease (COPD). Results: Using polychromatic flow cytome-
try, there was a 5-fold higher fraction of EpCAM-CD45-CD31-CD14- (mesenchymal) compared with
EpCAM+CD45-CD31-CD14- cells (epithelial) in unaffected postnatal human lung. The mesenchymal
fraction was composed primarily of single CD90+ and CD90+CD73+ cells both enriched in niche factors
CXCL12 and PDGFR฀. Immunofluorescence confirmed CD90+ cells in close proximity to EpCAM+ cells
some co-staining for pro-SPC in the alveolar region suggestive of an alveolar unit. Contained within the
CD90+ population, a subset co-expressed the pericyte marker CD146 with immunomodulatory proper-
ties able to internalize influenza virosomes, as well as live influenza virus. Postnatal CD90+CD146+
mesenchymal cells supported microvessel formation, whereas CD90+CD146+ mesenchymal cells from
COPD patients failed to do so. In congenital lung lesions, cystic airspaces and dysplastic alveolar regions
were marked with an expanded underlying thick interstitium of CD90+ and CD90+PDGFR฀+ cells.
Conclusion: These data provide important new information regarding the immunophenotypic identity of
key mesenchymal lineages and track their change in diverse setting of congenital lung lesions and other
airway abnormalities including COPD.
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Background: Our understanding of mesenchymal cell subsets and their function in 46 
human lung affected by aging and in certain disease settings remain poorly described.  47 
Methods: We use a combination of flow cytometry, prospective cell-sorting strategies, 48 
confocal imaging, and modeling of microvessel formation using advanced microfluidic 49 
chip technology to characterize mesenchymal cell subtypes in human postnatal and 50 
adult lung. Tissue was obtained from patients undergoing elective surgery for congenital 51 
pulmonary airway malformations (CPAM) and other airway abnormalities including 52 
chronic obstructive pulmonary disease (COPD). 53 
Results: In microscopically normal postnatal human lung, there was a 5-fold higher 54 
mesenchymal compared with epithelial (EpCAM+) fraction, which diminished with age. 55 
The mesenchymal fraction composed of CD90+ and CD90+CD73+ cells were enriched in 56 
CXCL12 and PDGFRα and located in close proximity to EpCAM+ cells in the alveolar 57 
region. Surprisingly, alveolar organoids generated from EpCAM+ cells supported by 58 
CD90+ subset were immature and displayed dysplastic features. In congenital lung 59 
lesions, cystic airspaces and dysplastic alveolar regions were marked with an underlying 60 
thick interstitium composed of CD90+ and CD90+PDGFRα+ cells. In postnatal lung, a 61 
subset of CD90+ cells co-express the pericyte marker CD146 and support self-assembly 62 
of perfusable microvessels. CD90+CD146+ cells from COPD patients fail to support 63 
microvessel formation due to fibrinolysis. Targeting the plasmin-plasminogen system 64 
during microvessel self-assembly prevented fibrin gel degradation but microvessels 65 
were narrower and excessive contraction blocked perfusion. 66 
Conclusion: These data provide important new information regarding the 67 
immunophenotypic identity of key mesenchymal lineages and their change in diverse 68 
setting of congenital lung lesions and COPD.  69 





Injury to lung parenchyma from various insults induces a general wound healing 72 
response whereby damaged or lost epithelial cells are replaced with new ones resulting 73 
in restoration of tissue architecture and function (28). The regenerative process in 74 
response to acute injury is dependent upon not only activation of lung epithelial cells but 75 
also a pool of lung mesenchymal cells that ensure recapitulation of normal architecture 76 
during the regeneration phase. However, failure in this 2nd phase of wound repair due to 77 
persistent perturbations in resident mesenchymal cells has been postulated to account 78 
for the etiology of many chronic lung diseases (7). Fate mapping studies in murines 79 
have shed light on the cellular make-up of the lung mesenchymal compartment (33). An 80 
emerging body of evidence points toward lipid-body interstitial fibroblasts or 81 
lipofibroblasts, marked by platelet derived growth factor A (Pdgfrα), being critical for both 82 
normal alveolar growth during development and proper regeneration after injury (4, 39, 83 
62). This key mesenchymal progenitor cell can be enriched using fibroblast growth factor 84 
10 (Fgf10), a pleiotropic molecule essential for regulating the growth of alveolar type II 85 
progenitor cells (16). However, these lipid-body Pdgfrα+ interstitial fibroblasts also are a 86 
source of myofibroblasts, a key effector cell type in the pathogenesis of pulmonary 87 
fibrosis following bleomycin injury in murines (17, 60). However, the presence of 88 
lipofibroblasts in human lung has recently been called into question (1, 52). Therefore, 89 
despite the promising data generated from the preclinical studies in murines, the 90 
translational nature of these studies to humans is unknown (54).  91 
Given the vast differences between murine and human lung with respect to 92 
development, architecture, cell composition and time scale of the repair response 93 
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following injury, there is an urgent need to assess the in vivo identity of mesenchymal 94 
lineages in diverse settings of lung injury in humans. It is of great clinical importance to 95 
characterize the cellular make-up of the mesenchymal compartment in human lung, to 96 
better understand the molecular mechanisms at work in certain disease settings that 97 
may represent an impediment to successful lung regeneration. This becomes 98 
increasingly more relevant as the use of cell-based therapies, some of which include 99 
non-resident mesenchymal cells, in the treatment of various lung disorders including 100 
idiopathic pulmonary fibrosis (IPF), emphysema and chronic obstructive pulmonary 101 
disease (COPD) increases (19, 21). 102 
 In the present study, we use a combination of polychromatic flow cytometric 103 
analysis, cell-isolation strategies, immunofluorescence analysis and microfluidic chip 104 
technology to identify and functionally characterize mesenchymal subtypes in postnatal 105 
human lung and their emergence in congenital lung disorders including congenital 106 
pulmonary airway malformations (CPAM) and other airway abnormalities. Furthermore, 107 
we compare our cellular findings with adult lungs of patients with COPD.  108 
109 
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MATERIALS AND METHODS 110 
Tissue samples and generation of single cells 111 
Lung tissue was obtained from pediatric patients undergoing elective surgery for 112 
congenital pulmonary airway malformation (CPAM) and other various airway 113 
abnormalities at Children’s University Hospital of Zurich (n = 19, age range: 5 days to 114 
192 months, Table 1, neonatal (1/19), infancy (11/19), childhood (3/19), puberty (4/19)). 115 
Samples from the unaffected matched tissue shown microscopically to have a normal 116 
microarchitecture with small alveoli and bronchiole were used for RNA, flow cytometric 117 
analysis, cell isolation and histological analysis. Matched samples from the lung lesions 118 
were used for comparative histology. For comparison to adult lung, we obtained 119 
uninvolved lung tissue from patients diagnosed with COPD (n = 15, Supplemental Table 120 
S1, Digital identification object, DOI:10.6084/m9.figshare.11799843; URL 121 
https://figshare.com/s/8da87d9d40436634c15e) or without COPD (n = 15, Supplemental 122 
Table S2, DOI: 10.6084/m9.figshare.11799843) undergoing surgical resection because 123 
of a primary or secondary lung tumor at Bern University Hospital, Division of Thoracic 124 
Surgery. All patients gave informed written consent for usage of surgical material for 125 
research purposes, which was approved by Ethics Commission of the Canton of Bern 126 
(KEK-BE:042/2015). Generation of single cells suspension for flow cytometric analysis 127 
and prospective fluorescence-activated cell sorting (FACS) was performed as previously 128 
described (8). Briefly, mechanically disaggregated tissue was further disaggregated 129 
enzymatically using a solution containing animal free collagenases I and II (Worthington 130 
Biochemicals) at 0.1 and 0.25% respectively. Collagenase II and I were chosen due to 131 
there activities for collagenase, caseinase, clostripain, and tryptic activities. To prevent 132 
cells from clumping during tissue digestion and improve cell recovery, we included 0.2 133 
Downloaded from journals.physiology.org/journal/ajplung at Hauptbibliothek Univ Zurich (144.200.017.040) on March 18, 2020.
6 
 
mg/ml deoxyribonuclease I (Biochemicals) in the digestion buffer. Following digestion, 134 
single cell suspensions were used for FACS or cryofrozen and stored at -150°C for later 135 
use. For some patients, a small section of the tissue was immersed in cell recovery 136 
solution (Qiagen) and stored at -80°C for isolation of tissue RNA and RT-qPCR at a later 137 
time point. 138 
 139 
Fluorescence-activated cell sorting and analysis 140 
To prospectively isolate mesenchymal cell subsets, single cells were resuspended in 141 
staining buffer (2% FBS/1 mM EDTA/0.09% sodium azide) and following Fc block 142 
(eBioscience) incubated with a panel of fluorescently conjugated human monoclonal 143 
antibodies: CD45, CD14, CD31, CD73, CD90, EpCAM (see Supplemental Table S5, 144 
DOI: 10.6084/m9.figshare.11799843). Using a BD FACS Aria III or BD FACS Aria, cells 145 
were sorted directly into collection buffer containing 20% FBS (Gibco, Life 146 
Technologies). Cell boundaries requiring the proper placement of gates to sort 147 
prospective cell populations was determined using fluorescence minus one (FMO) 148 
strategy and an unstained control (25, 41). Doublets and debris were excluded based on 149 
FSC and SSC profiles and dead cells were excluded based on 7-AAD (Supplemental 150 
Fig. S1, DOI: 10.6084/m9.figshare.11799843). In a second cohort of lung tissue was 151 
obtained from postnatal (n = 6; PL017-PL022) and adult lungs (n = 6; patient 10-15, see 152 
Table S1, DOI: 10.6084/m9.figshare.11799843), we added the following monoclonal 153 
human antibodies CD146, NOTCH3 and integrin β4 (CD104) (see Table S5, 154 
DOI:110.6084/m9.figshare.11799843) to our original antibody panel to further 155 
discriminate the cell populations of interest.  156 
 157 
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Primary mesenchymal cell culture 158 
FACS-sorted mesenchymal cell subsets were plated on regular tissue culture plastic 159 
precoated with 0.2% gelation solution (Sigma). Cells were expanded in chemically 160 
defined growth medium consisting of αMEM with ribonucleosides (Sigma) supplemented 161 
with 1% FBS, 200 mM L-glutamine (Gibco), 10 ng/mL of recombinant human fibroblast 162 
growth factor 2 (FGF2, Life Technologies), 20 ng/ml of recombinant human epidermal 163 
growth factor (EGF, Life Technologies), human insulin (1 mg/ml, Sigma). Media was 164 
formulated with antibiotic-antimycotic solution containing 10,000 units/mL of penicillin, 165 
10,000 µg/mL of streptomycin, and 25 µg/mL of Amphotericin B (Gibco). Cells were 166 
maintained in a humidified 37°C low oxygen (3% O2) incubator in 5% CO2 until reaching 167 
confluence. On day 6 after plating, the medium was carefully aspirated and replaced 168 
with fresh medium and regular media changes were performed biweekly.  169 
 170 
Histological and immunofluorescence analysis 171 
From donor human postnatal lung tissue (n = 8; PL003, PL004, PL006, PL008, PL012, 172 
PL013, PL014, PL019, see Table 1 for patient information), formalin-fixed tissue was 173 
dehydrated in a series of increasing ethanol concentrations and embedded in paraffin. 5 174 
µm sections were stained with a panel of human monoclonal antibodies targeting 175 
EpCAM, CD73, CD90, SPC and PDGFRα (see Supplemental Table S6, DOI: 176 
10.6084/m9.figshare.11799843). For antigen retrieval, slides were immersed in citrate 177 
buffer (10 mM, pH 5.5) and heated in a microwave. Following this, samples were 178 
washed 3X in TBS buffer. For blocking non-specific binding, slides were incubated for 30 179 
min at room temperature in blocking solution (3% goat serum, 0.5% casein, 0.1% NaN3 180 
in TBS buffer). Following this, primary antibodies were diluted in the same blocking 181 
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solution and applied in 100 µl aliquots per slide, covered with paraffin film and incubated 182 
overnight in a humidified chamber at 4°C. Slides were washed 3X in TBS + 0.1% Tween 183 
20 and secondary antibodies (see Supplemental Table 7, DOI: 184 
10.6084/m9.figshare.11799843) diluted in TBS + 0.1% Tween 20 + 0.1% Tween 20 185 
were applied in 100 µl aliquots to the slides and incubated for 3 hours in a humidified 186 
chamber at room temperature. Following this, all slides were washed 2X in TBS + 0.1% 187 
Tween 20. To counterstain nuclei, 100 µl of 4Ꞌ,6-diamidino-2-phenylindol (DAPI) 188 
(Molecular Probes, Invitrogen) solution was applied per slide for 30 seconds and 189 
washed for 5 min in TBS + 0.1% Tween 20. Slides were covered with EMS Shield Mount 190 
with antifading agent DABCO™ (Electron Microscopy Sciences) and edges sealed and 191 
slides kept in dark at 4°C prior to confocal microscopy. High resolution images were 192 
acquired with a Zeiss LSM 710 Confocal Microscope using the Zen software program 193 
(Zeiss). Images were collected as lsm files and imported into Imaris software Ver 7.6 194 
(Bitplane, CH). 195 
 196 
RNA extraction and real time quantitative PCR 197 
Total RNA was extracted from lung tissue and all mesenchymal cell subsets using 198 
RNeasy Mini Kit (Qiagen) to analyze gene expression using real time quantitative PCR 199 
(RT-qPCR). RT-qPCR was performed in triplicates with target-specific primers using 200 
TaqMan Gene Expression Assay (Applied Biosystems) or dye-based detection with 201 
GoTaq PCR master mix (Promega) on AB7500 FAST real-time PCR system (Applied 202 
Biosystems). Expression levels were normalized to 3 internal controls tested for 203 
expression stability across samples in each experiment using Expression Suite Software 204 
(Life Technologies). Relative expression was calculated by 2-ΔΔCT method. (Table S3-4 205 
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for complete primer list, DOI:110.6084/m9.figshare.11799843). For relative gene 206 
expression of the mesenchymal compartment, IMR-90 normal human fetal lung 207 
fibroblasts (Coriell Cell Repository, Camden, NJ) or normal human lung fibroblasts 208 
(ATCC® CCL-204™) and set to one.  209 
 210 
Mesenchymal differentiation 211 
For adipogenic induction, postnatal lung-derived CD90+ and CD90+CD73+ cells (P3-P4), 212 
as well as CD90+CD73+ cells from the bone marrow of a healthy adult were plated per 213 
well in a 6-well dish in regular culture medium and placed in a humidified chamber with 214 
5% CO2 at 37°C. After 24 hours, the wells were washed with PBS and fresh adipogenic 215 
maintenance medium consisting of DMEM/Low glucose (Gibco), 10 µg/mL human 216 
insulin (Invitrogen), 10% FBS, 1% Penicillin/Streptomycin was added. After 3 days, the 217 
medium was changed to an adipogenic induction (Gibco, ThermoFisher Scientific). 218 
Fresh media changes were made every 3 days up to 21 days. At day 21, cells were 219 
fixed with 4% paraformaldehyde and stained with Oil Red O (Sigma) to detect formation 220 
of lipid droplets (23). In separate wells, RLT lysis buffer (Qiagen) was added and cell 221 
lysis stored at -80°C for generation of RNA at a later time point. For osteogenic 222 
induction, cells were plated in a 6-well dish in DMEM supplemented with 10% FBS and 223 
1% Penicillin/Streptomycin. After 24 hours, media was changed and converted to 224 
osteogenic induction media (Gibco, ThermoFisher Scientific). Half-media changes were 225 
made every 3 days for a total of 21 days. At day 21, cells were fixed in 10% formalin and 226 
stained with 2 mM Alizarin Red S solution to detect extracellular calcium deposition. In 227 
separate wells, RLT lysis buffer (Qiagen) was added and cell lysis stored at -80°C for 228 
generation of RNA at a later time point. For chondrogenesis assay, early passage (P3-229 
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P4) 5x105 CD90+CD73+ and CD90+CD73- cells from postnatal lung were aliquot into 230 
15ml conical tubes and centrifuged at 300g for 5 minutes. Afterwards, media was 231 
removed and replaced with 500µl of chondrogenic induction media (Lonza, Switzerland). 232 
After 21 days, micromass pellets were fixed with 70% ethanol for 30 minutes and 233 
washed in PBS.  Pellets were embedded in GMA (Technovit 8100, Kuzler, Wehrheim, 234 
Germany) according to manufacturer’s protocol. Sections of 4 µm thickness were cut 235 
with a Reichert-Jung with a "C" knife blade and were mounted on a glass slide. A. 236 
Toluidine blue staining was performed using the following recipe. Natrium-Tetrabora. 237 
Toluidine blue 1g dissolved in 100 ml of milliQ water and filtered to remove any 238 
particulate. Toluidine solution was diluted 1:1 with milliQ water and applied to slides for 3 239 
min. Following staining, slides were washed 2 x 15 sec in 50% ethanol. Sections were 240 
allowed to air dry at room temperature and embedded in Eukitt. Micrographs were 241 
captured for each pellet using an Olympus BX50 microscope with a UPLAN FI objective 242 
10x magnification. For comparison, we included MSCs isolated from adipose tissue and 243 
bone marrow from healthy adults. 244 
 245 
Immunophenotype of cell subsets using flow cytometry 246 
Following expansion, mesenchymal cell subsets were harvested and re-suspended in 247 
FACS staining buffer. Following Fc block, cells were incubated with the following 248 
fluorescently conjugated human monoclonal antibodies used to detect mesenchymal 249 
lineages (see Table S5, DOI:110.6084/m9.figshare.11799843). Cells were incubated on 250 
ice in the dark for 30 minutes. To exclude dead cells and debris, 7-AAD was added. Cell 251 
acquisition was performed using a BD FACS LSRII SORP. For analysis, a minimum 252 
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1x104 events were collected and analyzed using FlowJo software version 10.7 (Tree 253 
Star).  254 
 255 
Virosome and liposome uptake  256 
Generation and characterization of influenza virosome and liposome formulations have 257 
been previously described (9). Briefly, Influenza virosomes were prepared as follows. In 258 
short: per ml of final formulation, 8 mg of DOPC (1,2-dioleoyl-sn-glycero-3-259 
phosphocholine; Merck, Darmstadt, Germany) and 1 mg of OPPE were dissolved in 100 260 
mM OEG in PBS pH 7.4 (52.7 mM phosphate, 82 mM NaCl). Inactivated Influenza 261 
A/Brisbane/59/2007 H1N1 virus was mixed with PBS and centrifuged for 1h at 18°C. 262 
The pellet of inactivated influenza virus was resuspended with 100 mM OEG-PBS pH 263 
7.4 for 10 min followed by sonication for 1 min at 30°C. This mixture was centrifuged for 264 
1h at 18°C to pellet down the nucleocapsid complex. The supernatant containing the 265 
solubilized influenza membrane proteins and lipids was used for virosome formulation 266 
and mixed with phospholipids at a concentration of 0.2 mg/ml hemagglutinin (HA). 267 
Virosome formation took place after removal of OEG detergent using 0.375 g per ml of 268 
formulation of SM2 Bio-Beads (BioRad) twice for 1 h and once for 30 min at room 269 
temperature whilst mixing at 100 rpm. Fluorescent virosomes were obtained by adding 270 
Atto647-PE as indicated prior to detergent removal to enable peptide incorporation. 271 
Liposomes were prepared similarly by leaving out the influenza virus component but 272 
following the same procedure. At the end of the process virosomes and liposomes were 273 
sterile filtered on 0.22 µm units (Millex-GP; Merck Millipore). To study uptake of 274 
influenza virosomes and liposomes, 105 mesenchymal cells from matched lung tissue 275 
were seeded per well in a six well dish (Corning). After 48 hours, cells were incubated 276 
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with influenza virosome particles (5 µg HA), liposome particles or PBS (vehicle control) 277 
for 18h. Uptake of nanoparticles was determined by measuring Atto-AF647 signal by 278 
flow cytometry (LSRII SORP, BD Biosciences). Data was analyzed using FlowJo V10 279 
(TreeStar, Ashland, OR, USA) software. A minimum of 1x104 events were collected.  280 
H1N1 influenza viral infection 281 
Influenza virus H1N1 A/PR/8/32 (ATTC, VR-1469) was propagated in MDCK II cell line 282 
(ATTCC, CRL-2936) and virus titers were assessed with a TCID50 assay using a crystal 283 
violet stain. To evaluate the susceptibility of postnatal lung-derived CD90+CD146+ 284 
mesenchymal cells towards influenza virus infection we used a flow cytometry approach. 285 
CD90+CD146+ mesenchymal cells were infected at a multiplicity of infection of 1 286 
TCID50/cell in serum-free medium supplemented with acetylated trypsin from bovine 287 
pancreas (Sigma, T6763) during 1h in a humidified 5% CO2 incubator at 37°C.  Next, 288 
the cells were harvested 16, 24 and 48h post-infection and stained intracellularly with a 289 
mouse anti-influenza nuclear protein (NP) antibody (ATCC, HB-65, clone H16-L10-4R5). 290 
N = 3, biological replicates. Data were acquired on a Canto flow cytometer (BD 291 
Bioscience) and analysed with the FlowJo ver10 software (Tree Star). Supernatants 292 
were collected and stored at -20°C until further analysis by the TCID50 assay. 293 
 294 
Vasculogenesis-on-chip 295 
The microfluidic device, chip fabrication process, cell seeding, chip maintenance, 296 
immunostaining and permeability assay have been previously described in detail [1], [2]. 297 
Briefly, HUVECs and postnatal- or COPD-derived CD90+CD146+ mesenchymal cells 298 
were suspended in 2 U/ml bovine plasma thrombin (Sigma) in endothelial basal medium 299 
2 (EBM2; Lonza) at final concentrations of 2x107 and 1x107 cells/ml, respectively. For 300 
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cell seeding, first, HUVECs, CD90+CD146+ cells, and fibrinogen solution were mixed at 301 
a ratio of 1:1:2 and immediately seeded into the central chamber. Next, a 1:1 mixture of 302 
CD90+CD146+ cells and fibrinogen solution was immediately loaded in the side 303 
chambers. After 10 min, EGM2 was loaded in microchannels and the reservoirs were 304 
filled. All chips were incubated for 7 days. The experiments were carried out from three 305 
different postnatal and COPD-derived biological donors. After 7 days of co-culturing, 306 
some of the chips were fixed for immunostaining against PECAM-1, αSMA, F-actin and 307 
DAPI. The remaining chips were used for perfusion assay with 70 kDa RITC-dextran in 308 
live vessels. In separate experiments, HUVECs and CD90+CD146+ cells from postnatal 309 
or COPD patients were seeded in fibrin gels within the microfluidic device, as described 310 
above. To examine the impact of antifibrinolytic agent epsilon-Aminocaproic acid 311 
(EACA) (Sigma) on vessel formation, EACA was added to the cell culture medium at a 312 
final concentration of 200 µg/ml. EACA-EBM2 medium was used in the microfluidic 313 
device for coculturing HUVECs and CD90+CD146+ cells starting from day 0 until day 6. 314 
After 7 days of culturing in the presence of EACA, chips were prepared for 315 
immunostaining or for perfusion measurements, as described above. 316 
 317 
T-cell activation assay  318 
Peripheral blood mononuclear cells (MNCs) were isolated from healthy blood bank 319 
donors using Ficoll-PaqueTM Plus (GE Healthcare Life Sciences, Switzerland) density 320 
gradient centrifugation. Following this, highly purified CD3+ T cells were isolated from the 321 
MNC pellet using the EasySep™ Human T Cell Isolation Kit (StemCell Technologies) 322 
according to the manufacturer’s instructions. Healthy donor T cells were labeled with 0.5 323 
µM CFSE (eBioscience) according to the manufacturer’s instructions. CFSE-labeled 324 
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CD3+ T cells (2x105) were stimulated with CD3/CD28/CD2 activator beads (Stemcell 325 
Technologies) in 96-wells U-bottom plates in T cell media (Immunocult XF, StemCell 326 
Technologies) supplemented with 10 ng/ml of recombinant human IL-2 (Peprotech) at 327 
37°C and 5% CO2. Separately, mesenchymal cell subsets were gamma irradiated (10 328 
Gy) and in separate wells, 4x104, 2x105 or cells were added to wells containing 2x105 329 
CFSE-labeled T cells activated with CD3/CD28/CD2 activator beads. Following this, co-330 
cultures were treated with 50 ng/ml of rhTNFα (Gibco) and 50 ng/ml of rhIFNγ (Gibco) or 331 
vehicle. After 5 days of culture at 37°C and 5% CO2, cell-free supernatant was collected, 332 
frozen and stored at -20°C for later analysis. Cells were harvested and were stained with 333 
a cocktail of antibodies: anti-human CD45, anti-human CD4 and anti-human CD8 (see 334 
e-Table 5). Cell viability was determined using 7-AAD (eBioscience) according to the 335 
manufacturer’s protocol. Cells were analyzed for proliferation using CFSE-dilution 336 
patterns and for phenotype on a BD LSRII SORP(BD Biosciences). For analysis of 337 
phenotypic markers, we used FlowJo software ver 10.1 (TreeStar) and precursor 338 
frequencies of activated CD4+ and CD8+ T cells were calculated. A minimum of 1x105 339 
events were collected for analysis.  340 
 341 
Metformin treatment 342 
Early passage CD90+CD146+ cells from surgically resected early postnatal lung or 343 
COPD lung tissue were seeded at 1 x 105 cells per well in regular culture media. After 344 
24 hours, cells were growth arrested by replacing regular culture media with serum free 345 
media. After 24 hours, cells were treated with 5 ng/mL of recombinant human TGFβ1 346 
(Gibco) without or with 0.5mM metformin (StemCell Technologies) over 72 hours. 347 
TGFβ1 and metformin were refreshed at each media change. After 72 hours, RLT lysis 348 
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buffer was added to each well and cell lysates were stored at -80°C for generation of 349 
RNA at a later time point. In separate experiments, early passage CD90+CD146+ 350 
mesenchymal cells from postnatal lung or COPD lung tissue, as well as MSCs from 351 
bone marrow and adipose tissue (CellnTec, Bern Switzerland) were seeded at 2 x 105 352 
cells per well in a 6-well dish in regular culture medium. After 24 hours, cells were 353 
converted to adipogenic induction media (Gibco), as described above, without or with 354 
0.5 mM metformin. Fresh media changes were made every 3 days up to 21 days. 355 
Metformin was added at each media change. At day 21, RLT lysis buffer (Qiagen) was 356 
added and cell lysis stored at -80°C for generation of RNA at a later time point.  357 
 358 
Statistical analysis 359 
Data are expressed as mean ± SD. Comparisons between two groups were carried out 360 
using the parametric student’s two-tailed paired or unpaired t-test for normally distributed 361 
data. If data were not distributed normally, a nonparametric Wilcoxon signed-rank test 362 
was used between the two groups. One-way analysis of variance (ANOVA) followed by 363 
Newman-Keuls post hoc test was used for analysis of more than two groups. The 364 
numbers of samples (biological replicates) per group (n), or the numbers of experiments 365 
(technical replicates) are specified in the figure legends. To test whether there was a 366 
correlation between age and mesenchymal and epithelial compartments, Pearson’s 367 
correlation coefficient was used, assuming a normal distribution of the data. Data was 368 
analyzed using GraphPad Prism 8 software. Statistical significance is accepted at 369 
P<0.05. 370 
371 




Cellular identification of mesenchymal subsets in human postnatal lung 373 
We set out to identify and characterize mesenchymal lineages in postnatal lung tissue 374 
obtained from pediatric patients undergoing elective surgery for congenital lung lesions 375 
and other airway abnormalities (Figure 1A, see Supplemental Table 1 and Fig. S1, DOI: 376 
10.6084/m9.figshare.11799843). Flow cytometric analysis of unaffected resected lung 377 
tissue determined microscopically to have normal microarchitecture with small alveoli 378 
and bronchiole revealed a prominent mesenchymal fraction based on the marker profile 379 
EpCAM-CD45-CD31-CD14- (gate R4, referred to as EpCAM-), as shown in the 380 
representative bivariate flow cytometric plot in Figure 1B (Supplemental Fig. S2 for full 381 
gating strategy, DOI: 10.6084/m9.figshare.11799843). Interestingly, the EpCAM- fraction 382 
was 4.8 fold higher compared to EpCAM+ fraction (EpCAM-, 24.2±15% versus EpCAM+, 383 
5.01±2.8%, respectively, Figure 1C). With age the EpCAM- fraction declined significantly 384 
(Figure 1D). The decline in the EpCAM- was confirmed in adult human lung (Figure 1E 385 
and Supplemental Fig. S3A-E, DOI: 10.6084/m9.figshare.11799843)). In adult human 386 
lung, the EpCAM- fraction was 2.3±2.4% of live cells compared to 6.8±4.2% for the 387 
EpCAM+ fraction (Figure 1F and Supplemental Fig. S3A-E, DOI: 388 
10.6084/m9.figshare.11799843). We further characterized the EpCAM- fraction based 389 
on marker expression of 5`ecto-nucleotidase CD73 (NT5E) and membrane glycoprotein 390 
CD90 (THY-1), strong candidate markers for the direct identification of multipotent 391 
mesenchymal cells within various human tissues (12). As shown in a representative 392 
bivariate plot (Figure 1G), single CD90+ cells are the predominate cell subset 393 
(34.7±19.2%) followed by CD90+CD73+ (15.8±19%), whereas single CD73+ (1.5±1.3) 394 
cells were rare (Figure 1H). Interestingly, the % of these fractions change with age 395 
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(Figure I, J), whereby the majority of cells switch from CD90+CD73- to CD73+ with or 396 
without CD90+ adult lung (Supplemental Fig. S3F, DOI: 10.6084/m9.figshare.11799843). 397 
Next, we sought to visualize the anatomical localization of CD90+ subsets in human 398 
postnatal lung tissue. Standard H&E staining of microscopically normal postnatal lung 399 
tissue demonstrate a normal alveolar region (Figure 1K). Immunofluorescence (IF) 400 
staining and confocal microscopy show single CD90+ cells, as well as CD90+CD73+ cells 401 
in close proximity to EpCAM+ cells in the alveolar region (Figure 1L). These data show 402 
that the pulmonary mesenchyme, although often overlooked, represents a major cellular 403 
constituent in early postnatal human lung that dramatically declines with aging.  404 
 405 
Postnatal lung CD90+ mesenchymal cells enriched in niche factors PDGFRα and 406 
CXCL12 yet possess diminished adipogenic differentiation capacity 407 
FACS analysis shows that that there are two distinct CD90+ populations based on CD73 408 
expression. FACS-purified CD90+CD73+ and CD90+CD73- subsets were expanded 409 
using a chemically defined media for mesenchymal cells (Figure 2A and Supplemental 410 
Table S8, DOI: 10.6084/m9.figshare.11799843). Morphologically, both subsets appear 411 
pericyte-like comprised of a central nucleus with small, finger-like branches (Figure 2B). 412 
Characterization of these two subsets show higher mRNA levels of CXCL12 and 413 
PDGFRα, key niche factors shown to contribute to alveolar development and 414 
regeneration in murine lungs, in both CD90+CD73- and CD90+CD73+ cells compared to 415 
lung tissue (Supplemental Fig. S4A, DOI: 10.6084/m9.figshare.11799843) (4, 45). 416 
Expression of FGF10 and IL-6, important morphogens in lung development in mice (16) 417 
and leptin receptor (LEPR), which marks a subset of bone marrow-derived MSCs also in 418 
mice (22), were reduced in CD90+CD73- and CD90+CD73+ cells compared to lung 419 
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tissue. Although the expression level of GLI1, a zinc finger protein marking 420 
mesenchymal cells with a pericyte/mesenchymal stem cell (MSC) origin in mice (29), 421 
was elevated in both CD90+CD73- and CD90+CD73+ cells compared with human lung 422 
embryonic fibroblasts, neither population were enriched in common pericyte markers 423 
RGS5 and desmin; nor makers of differentiated cell types αSMA (ACT2) and calponin 424 
(CNN1). There were no difference in the expression of other mesenchymal markers 425 
shown to be important for early lung development such as WNT5A, FGFR1, beta-426 
catenin and NOGGIN compared with tissue (data not shown). Since CD90 and CD73 427 
are critical markers used to define mesenchymal stem/stromal cells (MSCs), we 428 
characterized the mesenchymal differentiation potential of the CD90+ subsets. Despite 429 
both CD90+CD73- and CD90+CD73+ cells being enriched in PDGFRα, neutral lipid 430 
formation was diminished compared with CD90+CD73+ MSCs from human bone marrow 431 
(BM) of healthy adults (23). By contrast, the osteogenic potential of both subsets is 432 
comparable to BM-derived CD90+CD73+ MSCs (Figure 2D). Finally, using a micromass 433 
pellet assay, the chondrogenic differentiation potential of CD90+CD73+ and CD90+CD73- 434 
subsets was similar to BM-derived CD90+CD73+ MSCs and adipose tissue-derived 435 
MSCs based on Toluidine blue staining (Figure 2E-F). 436 
 437 
CD90+ and CD90+PDGFRα+ mesenchymal cells fill thickened interstitial spaces in 438 
airway and dysplastic alveolar epithelium  439 
Recent work in murines demonstrate distinct mesenchymal lineages promote epithelial 440 
renewal and myofibrogenesis following injury (62). To investigate this, we developed an 441 
alveolar organoid system (4). We seeded CD90+ mesenchymal cells with autologous 442 
EpCAM+CD73+ epithelial stem/progenitor cells FACS-purified from postnatal human lung 443 
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in matrigel (Figure 3A). Three weeks after differentiation in alveolar induction media, 444 
organoid structures expressing E-cadherin+ (green) were surrounded by PDGFRα+ 445 
mesenchymal cells (Figure 3B). In microscopically normal alveolar region of postnatal 446 
lung, CD90+ cells co-expressing PDGFRα can be observed, although very few (Figure 447 
3C). Significant overexpression of key transcription factors SOX2, SOX9 and TP63 448 
along with KRT5 was observed in organoid structures compared to native lung tissue 449 
suggestive that organoid structures are dysplastic. To determine whether CD90+ subset 450 
become activated after injury, we performed histological and IF staining of lung lesions 451 
resected from patients diagnosed with CPAM and other airway abnormalities. Standard 452 
H&E and IF staining of lung sections obtained from microscopically normal postnatal 453 
lung tissue show normal airway and alveolar regions (Supplemental Fig. S5A-C, DOI: 454 
10.6084/m9.figshare.11799843). By comparison, H&E staining of matched lesions 455 
resected from CPAM tissues from two patients with concomitant respiratory infection 456 
show significant areas of macrocystic and microcystic airway and alveolar lesions 457 
(Figure 3E, H and Supplemental Fig. S1B-C, DOI: 10.6084/m9.figshare.11799843). In 458 
the patient with CPAM/chronic infection, IF staining shows thickened airway interstitium 459 
filled with CD90+ cells, some of which also co-stain for PDGFRα (Figure 3F-G). In the 460 
patient with CPAM/RSV infection, a greater abundance of CD90+ cells co-staining for 461 
PDGFRα was observed in the alveolar region (Figure 3I-J). Comparable histological 462 
observations were noted in a third patient with chronic bronchiolitis, whereby cystic 463 
airspaces lined with a simple layer of cuboidal EpCAM+ cells contained an underlying 464 
extensive network of CD90+ mesenchymal cells, some co-staining for PDGFRα (Figure 465 
3K-M). In this same patient, we noted significant expansion of CD90+PDGFRα+ 466 
mesenchymal cells underlying thickened airway lining (Supplemental Fig. S5D-F, DOI: 467 
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10.6084/m9.figshare.11799843), as well as in the dysplastic alveolar region 468 
(Supplemental Fig. S5G-I, DOI: 10.6084/m9.figshare.11799843). Finally, in lungs of a 469 
patient with lobar emphysema, we also note dysplastic alveolar regions marked by 470 
expanded CD90+ cells where some co-stain for PDGFRα (Supplemental Fig. S5J-L, 471 
DOI: 10.6084/m9.figshare.11799843). Taken together, these data show that congenital 472 
lung lesions exhibit a pronounced expansion in mesenchymal cells. The contribution of 473 
CD90+ mesenchymal cells to disease etiology and pathogenesis of congenital lung 474 
lesions warrants further investigation.  475 
 476 
Influenza A virus infects and replicates in postnatal lung CD90+CD146+ 477 
mesenchymal cells 478 
Based on their anatomical location in the alveolus, we hypothesized that CD90+ subsets 479 
may contain pericytes, as previously shown at the ultrastructural level (57). FACS 480 
analysis shows that 21.9±16.9% of CD90+CD73- and 5.4±4.4% of CD90+CD73+ cells 481 
express the pericyte maker CD146 but not NOTCH3 (Figure 4A-B). At the surface level, 482 
CD90+CD73-CD146+ cells expressed higher levels of PDGFRβ, CD166 and podoplanin 483 
(PDPN) compared with CD90+CD73-CD146- cells (Figure 4C). CD146+ pericytes are 484 
essential for tissue repair following injury by participating in vasculogenesis (12) and 485 
regulation of host immune system (6). Recently, the use of virosomes and liposomes as 486 
nanocarriers to deliver cargo to lung tissue in a cell type specific manner has been 487 
described (9). While influenza virosomes target specific immune and parenchymal cell 488 
types of the respiratory tract, less is known regarding their interaction with 489 
nonparenchymal mesenchymal cell types. To test this, we exposed postnatal lung-490 
derived CD90+CD73-CD146+ mesenchymal cells to liposomes or influenza virosomes 491 
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conjugated to the fluorochrome Atto647 (Figure 4D). FACS analysis shows a greater 492 
uptake of influenza virosomes compared with liposomes by CD90+CD73-CD146+ (Figure 493 
4D). Interestingly, H1N1 influenza virosome (Brisbane A strain) demonstrated the 494 
greatest tropism, whereas H3N2 (Texas strain) showed the lowest tropism (Figure 4E). 495 
Virosome uptake did not induce changes in cell surface expression of intercellular 496 
adhesion molecule 1 (ICAM1, CD54) nor the HLA major histocompatibility complex, 497 
class II, DR Alpha (HLA-DRA) (data not shown). To determine whether CD90+CD73-498 
CD146+ mesenchymal cells also represent a target for viral tropism, we infected cells 499 
with live H1N1 influenza virus (PR8 strain). FACS analysis shows influenza nuclear 500 
protein (NP) expression at 16, 24 and 48 hours post-infection demonstrating H1N1 was 501 
capable of infecting postnatal lung-derived CD90+CD73-CD146+ cells compared to mock 502 
infected cells (Figure 4F-H). Culture supernatants isolated from H1N1 infected 503 
CD90+CD73-CD146+ mesenchymal cells as early as 8 hours post infection and up until 504 
48 hours post infection demonstrate that H1N1 actively replicates inside infected cells 505 
(Figure 4I). To further address immune modulation of mesenchymal subsets, we tested 506 
whether CD90+CD73-CD146+ and CD90+CD73-CD146- mesenchymal cells block that 507 
activation of T cells. For this, we cultured both mesenchymal cell subsets in the 508 
presence of carboxyfluorescein succinimidyl ester (CFSE-)-labelled CD3+ T cells derived 509 
from peripheral blood mononuclear cells of healthy donors stimulated with 510 
CD3/CD28/CD2 T cell activator beads (Supplemental Fig. S6A, DOI: 511 
10.6084/m9.figshare.11799843). Both postnatal CD90+CD73-CD146+ and CD90+CD73-512 
CD146- mesenchymal cells were able to arrest activation of healthy CD4+ and CD8+ T 513 
cells in a dose-dependent manner (Supplemental Fig. S6B-F, DOI: 514 
10.6084/m9.figshare.11799843). This was also confirmed with CD4 and CD8 T cells 515 
Downloaded from journals.physiology.org/journal/ajplung at Hauptbibliothek Univ Zurich (144.200.017.040) on March 18, 2020.
22 
 
isolated from human lung activated using staphylococcus enterotoxin B (Supplemental 516 
Fig. S6G-H, DOI: 10.6084/m9.figshare.11799843). Taken together, these data 517 
underscore the dynamic nature CD90+CD146+ mesenchymal cells in postnatal human 518 
lung being equipped to function as immune sensing cells able to respond to changes in 519 
the pulmonary microenvironment. 520 
 521 
CD90+CD146+ mesenchymal subset is maintained in COPD  522 
FACS analysis shows that the mesenchymal fraction diminishes with age. In chronic 523 
lung disease associated with fibrosis, there is evidence of an important role of the 524 
mesenchymal compartment (6, 33). Whether this also is the case in chronic obstructive 525 
pulmonary disease (COPD) is unknown. To investigate this, we performed flow 526 
cytometric analysis on uninvolved regions of surgically resected tissue obtained from 527 
lung cancer patients diagnosed with COPD according to GOLD guidelines. FACS 528 
analysis shows there was an increase in the EpCAM- mesenchymal fraction (Figure 5A) 529 
in COPD compared with non-COPD resected lung tissue (COPD, 11.7±15 versus non-530 
COPD, 2.3±2.4%, p<0.0051) (Figure 5B). This coincides with an increase in EpCAM-531 
/EpCAM+ ratio in COPD compared with non-COPD controls (COPD, 4.9±12% and non-532 
COPD, 0.41±0.3%, respectively) (Figure 5C). The distribution of mesenchymal subtypes 533 
based on subgating for CD90 and CD73 was not altered in COPD (Figure 5D). 534 
Surprisingly, CD146 expression in CD90 and CD73 subsets increased in COPD 535 
compared with non-COPD controls (Figure 5E). FACS-purified CD90+CD146+ cells from 536 
COPD patients shows a distinct myogenic-like morphology (Figure 5F) and 537 
downregulate the expression of GLI1, PDPN and the lung morphogen FGF10 (Figure 538 
5G). Decreased levels of angiopoietin 1 (ANGPT1), which is critical for normal vascular 539 
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development, also were found in CD90+CD146+ cells in COPD (Figure 5G). Recently it 540 
was shown that first-line antidiabetic drug metformin inhibits the fibrotic effects of TGFβ1 541 
on human lung fibroblasts while inducing lipogenic differentiation (27). When exposed to 542 
TGFβ1, CD90+CD146+ cells from COPD upregulated expression of fibroblast activation 543 
protein alpha (FAP) and collagen 1A1, which was not blocked by metformin (Figure 5H). 544 
In addition, CD90+CD146+ cells from COPD or postnatal lung tissue lack adipogenic 545 
potential and metformin treatment had no effect on the lack of adipogenesis 546 
(Supplemental Fig. S7, DOI: 10.6084/m9.figshare.11799843). In addition, metformin did 547 
not enhance adipogenesis in control BM- or adipose-derived MSCs. 548 
 549 
CD90+CD146+ mesenchymal cells in COPD fail to support microvessel formation 550 
Injury to the lung impairs the function of different subsets of tissue resident 551 
mesenchymal cells (10, 11). In COPD, there is evidence of vascular dysfunction not 552 
explained by defects in the vascular endothelium (35). Using a three dimensional (3D) 553 
microfluidic device, we next asked whether CD90+CD146+ cells support microvessel 554 
formation de novo and whether this function is impaired in COPD (Figure 6A-B) (61). 555 
Imaging of the central chamber of the microfluidic device shows that postnatal 556 
CD90+CD146+ cells support self-assembly of 3D networks consisting of lumen-forming 557 
HUVECs stained with the pan-endothelial maker CD31 (circular image, Figure 6C). By 558 
contrast, CD90+CD146+ cells from COPD fail to support 3D vascular network formation 559 
(Figure 6D). Serial images of vascular network in the central chamber supported by 560 
postnatal CD90+CD146+ cells shows communication between CD31+ HUVECs (red) with 561 
αSMA+ pericyte-like cells (green) located on the abluminal surface (Figure 6E). An 562 
orthogonal view of merged images shows open lumens (Figure 6G). By contrast, COPD 563 
Downloaded from journals.physiology.org/journal/ajplung at Hauptbibliothek Univ Zurich (144.200.017.040) on March 18, 2020.
24 
 
CD90+CD146+ cells (αSMA, green) degrade the fibrin gel resulting in the formation of 2D 564 
cell layer with CD31+ HUVECs (red) on the bottom of the microfluidic device within the 565 
central chamber, shown as serial images (Figure 6F) with no evidence of lumen 566 
formation (Figure 6H). Microvasculature structures supported by postnatal 567 
CD90+CD146+ cells were perfusable confirmed following application of 70 kDa RITC-568 
dextran, attaining a permeability coefficient of 2.1 ± 2 x10-4 cm/s (Figure 6I, left panels 569 
and Supplemental Video S1, DOI: 10.6084/m9.figshare.11799843). Single postnatal 570 
CD90+CD146+ cells within fibrin gel in the side chamber do not form lumens but rather 571 
migrate towards the central chamber in support vessel self-assembly (Supplemental Fig. 572 
S8A and Supplemental Video S2, DOI: 10.6084/m9.figshare.11799843). Three-573 
dimensional nature of the vascular structure formed in the central chamber was 574 
illustrated following volume rendering (Supplemental Fig. S8A, DOI: 575 
10.6084/m9.figshare.11799843). By contrast, structures supported by COPD 576 
CD90+CD146+ cells were not perfusable (Figure 6I. right panels and Supplemental 577 
Video S1, DOI: 10.6084/m9.figshare.11799843), as well, cells in the side chamber also 578 
degrade the fibrin gel and fail to migrate (Supplemental Fig. S8B, and Supplemental 579 
Video S2, DOI: 10.6084/m9.figshare.11799843). 3D volume rendering confirms the 580 
single 2D layer formed in the central chamber (Supplemental Fig. S8B, DOI: 581 
10.6084/m9.figshare.11799843). To further address fibrinolysis in COPD cells, we 582 
treated cocultures with the antifibrinolytic lysine analogue epsilon-aminocaproic acid 583 
(EACA), which inhibits the conversion of plasminogen to plasmin. Targeting of the 584 
plasmin-plasminogen system with EACA did not prevent postnatal CD90+CD146+ cells 585 
from supporting 3D vascular network formation (Figure 6J). Importantly, EACA 586 
prevented COPD CD90+CD146+ cells from degrading the fibrin extracellular matrix 587 
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enabling the formation of microvessel-like structures (Figure 6K). Z-stack projection of 588 
merged channels from the central chamber shows open lumens (Figure 6L-M). The 589 
morphology of EACA treated COPD CD90+CD146+ cells in the fibrin gel in the side 590 
chamber was similar to their postnatal lung counterparts; however, αSMA was not 591 
detected in 3D vascular network generated from postnatal CD90+CD146+ cells 592 
(Supplemental Fig. S8C-D, DOI: 10.6084/m9.figshare.11799843). Microvessel-like 593 
structures formed with postnatal CD90+CD146+ cells in the presence of EACA were 594 
perfusable (Figure 6N); however, the permeability co-efficient increased by a factor of 595 
3.5 (7.01 ± 6.92 x10-4 cm/s, n = 4). By contrast, microvessel-like structures supported by 596 
COPD CD90+CD146+ cells in the presence of EACA were not perfusable due to 597 
contraction of the fibrin gel (Figure 6N, right panels and Supplemental Fig. S8D-E, DOI: 598 
10.6084/m9.figshare.11799843). Second, the microvessel-like structures that formed in 599 
the central chamber were narrower compared with CD90+CD146+ cells from postnatal 600 
lung (Figure 6O). This suggests that direct interaction with the ECM activate biochemical 601 
and mechanosensing cues unmasking the pathological phenotype of mesenchymal cells 602 
from COPD lungs. Collectively, CD90+CD146+ pericyte-like cells may represent a novel 603 
target in the pathogenesis of COPD. 604 
  605 




In this study, we used flow cytometry to identify and quantify distinct mesenchymal 607 
lineages in human postnatal and adult lung. Single CD90+ cells and CD90+CD73+, the 608 
major mesenchymal cell types enriched in microscopically normal postnatal lung. The 609 
spatial proximity of CD90+ mesenchymal cells to EpCAM+ progenitor cells suggests they 610 
could function as niche-supporting cells in the alveolus. At the mRNA level, postnatal 611 
CD90+ subsets are enriched in PDGFRα. A loss of alveolar PDGFRα+ mesenchymal 612 
cells is a signature feature in bronchopulmonary dysplasia (BPD) (43), a serious lung 613 
disease prevalent in preterm infants characterized by a reduction in gas exchange 614 
surface area due to oversimplified or diminished alveoli (34). Surprisingly, organoids 615 
generated in matrigel from single EpCAM+ progenitor cells supported by autologous 616 
CD90+ subsets from microscopically normal postnatal lung failed to recapitulate normal 617 
alveolar structures. Second, structures were dysplastic at the gene level (59). Although 618 
expressing PDGFRα, CD90+ subsets possess limited adipogenic potential when 619 
compared to FACS-purified CD90+CD73+ cells from human bone marrow (23). These 620 
findings are in contrast to murines where alveolar CD90+PDGFRα+ lipid-laden 621 
lipofibroblasts in direct contact with ATII progenitor cells provide lipid and other critical 622 
paracrine factors necessary for normal alveolar development, as well as regeneration 623 
following injury (4, 62). Tcf21, a basic helix-loop-helix transcription factor, was used to 624 
identify cells with lipofibroblast potential (40). We did not determine whether CD90+ 625 
perivascular-like cells express Tcf21. Despite this, it will be important to investigate 626 
whether forced expression of Tcf21 induces a lipid formation in CD90+ perivascular-like 627 
cells in human lung. Immunostaining analysis of congenital lung lesions and other 628 
airway abnormalities revealed an unexpected expansion in CD90+ and CD90+PDGFRα+ 629 
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mesenchyme in thickened interstitial spaces between cysts, as well as dysplastic 630 
alveolar regions. Although mesenchymal spindle-shaped cells in CPAM lesions have 631 
been described using standard histological staining, their cellular identity and role in 632 
disease pathogenesis is not known (15, 42). Recently, Swarr and colleagues performed 633 
the first comprehensive transcriptome-wide analysis of various congenital lung lesions 634 
demonstrating dysregulated expression of genes related to RAS and PI3K/AKT/mTOR 635 
pathway, together with a cell-autonomous defect in the growth and airway differentiation 636 
of EpCAM+ progenitor cells (51). However, an involvement in lung mesenchyme was not 637 
described. Besides targeting epithelial wound healing, PI3K/mTOR pathway is 638 
upregulated in lung fibroblasts contributing to lung fibrosis following bleomycin injury 639 
(37). Whether PI3K/AKT/mTOR pathway also is at play in CD90+ and CD90+CD73+ 640 
mesenchymal cells contributing to disease pathogenesis in congenital lung lesions 641 
requires further investigation. 642 
A fraction of cells within the CD90+ subsets expressed the common pericyte 643 
surface marker CD146 and was enriched in GLI1, a marker of perivascular progenitor 644 
cells (29). FACS-purified CD90+CD146+ cells from microscopically normal postnatal lung 645 
support the self-assembly of patent microvessels and possess immune regulatory 646 
function (26). In COPD, we noted an increase in the mesenchymal fraction, which 647 
coincided with an increase in CD90+CD146+ subset compared with adults without 648 
COPD. To date, the pathogenesis of COPD has primarily focused on defects in airway 649 
basal cells (13, 20, 50) and the immune system (5). However, various changes in the 650 
pulmonary vascular system also have been reported (30, 36). Increased levels of 651 
soluble CD146 in plasma and bronchioalveolar lavage (BALF) were found in smokers 652 
with COPD (31). The adhesion molecule CD146 provides support for the growing 653 
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vasculature, yet the vascular supportive function of CD90+CD146+ cells in COPD was 654 
abolished due to extensive fibrinolysis. A deregulated fibroblast repair capacity may be 655 
critically involved in the pathogenesis of emphysema (55). FACS-purified CD90+CD146+ 656 
cells were expanded on dishes coated with gelatin rather than a stiff plastic culture 657 
substrate. Despite clear differences in their morphology on 2D plastic, surprisingly there 658 
was no difference in the expression level of the myofibroblast marker αSMA between 659 
postnatal and COPD CD90+CD146+ cells. We also did not detect any differences in 660 
basal expression of enzymes involved in extracellular matrix degradation such as 661 
MMP2, MMP9 and SERPINE2 (data not shown). There were clear differences in matrix 662 
mechanosensing properties between postnatal and COPD CD90+CD146+ cells 663 
suggesting that COPD-derived cells “sense” stiffness activating a fibrinolytic state. 664 
Properties of the matrix play a critical role in determining cell fate (18). Fibrin gels are 665 
mildly compliant. The Young modulus (mechanical stress per strain) of the fibrin network 666 
is less than 1 kPa (14). This is similar to healthy lung tissue with a general stiffness of 667 
around 2kPa (49). Targeting the plasmin-plasminogen system with the lysine analogue 668 
EACA blocked COPD CD90+CD146+ cells from degrading fibrin gel thus enabling the 669 
generation of 3D microvessel-like structures, although narrower compared with 670 
CD90+CD146+ cells from postnatal lung. Despite this, the contractile property of COPD 671 
CD90+CD146+ cells prevented perfusion. Therefore, direct interaction with the ECM 672 
activate biochemical and mechanosensing cues in COPD CD90+CD146+ cells 673 
unmasking their pathological state, which may go undetected in 2D culture systems. 674 
Interestingly, human PDGFR-β positive pericytes derived from lungs of patients with 675 
idiopathic pulmonary fibrosis (IPF) demonstrated similar features of increased 676 
invasiveness and response to exposure to TGFβ1 (58). 677 
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Our study has several limitations. First, although our FACS panel enables us to 678 
properly discriminate and isolate mesenchymal cell subsets, it is limiting due to an 679 
inability to follow the trajectory of CD90+CD146+ subset during chronic lung injury. In 680 
rodents, exposure to high oxygen levels disrupts the dual immune regulating and 681 
vascular supportive function of neonatal-lung derived CD146+ mesenchymal stromal 682 
cells (11). Similar findings were recently reported for a population of CD146 positive 683 
mesenchyme cells purified from human fetal lung when exposed to high levels of oxygen 684 
(38). The data supports a local source of mesenchymal cells versus a circulating source 685 
from the bone marrow contributing to adverse remodeling following lung injury (10). 686 
Therefore, it is reasonable to conclude that the CD90+ population identified in our report, 687 
which contain a subpopulation positive for CD146 with immune regulatory properties 688 
(26), could be precursors to the cells found in tracheal aspirates of neonates following 689 
lung injury from bronchopulmonary dysplasia (BPD)(46). An unresolved question is 690 
whether MSC-like cells arise from a perivascular location in the bronchial vasculature or 691 
alveolar compartment found on small vessels (10, 44). Another limitation is the limited 692 
marker profile to prospectively identify cells with pericyte-like function. We found that the 693 
common lymphendothelial marker PDPN is highly upregulated on postnatal 694 
CD90+CD146+ cells. PDPN has been described to be expressed on a wide variety of 695 
cells including fibroblast reticular cells and type I lung epithelial cells (2). In murines, 696 
PDPN positive fibroblastic reticular cells co-expressing PDGFRβ in lymph nodes are 697 
responsible for maintaining vascular integrity. Loss of PDPN leads to increased 698 
bleeding. PDPN-expressing arteriolar pericytes have been described in bone marrow of 699 
murines (53). At the mRNA level, PDPN is downregulated in CD90+CD146+ cells in 700 
COPD. Whether downregulation in PDPN contributes to the dysregulated perivascular 701 
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function is unknown. We also show that GLI1, which labels a subset of perivascular 702 
progenitors (29), is highly upregulated on postnatal CD90+CD146+ cells. Therefore, 703 
PDPN may represent a marker to enrich lung pericyte progenitors not fibroblasts. 704 
Recently, CD36 and CD97 were used to identify quiescent fibroblasts in human lung 705 
from patients with IPF (24). Future studies are needed to determine whether CD36 and 706 
CD97 are also expressed by perivascular-like cells identified in our study. 707 
Despite these limitations, we noted a 5-fold reduction in the mesenchymal fraction 708 
with age, underscoring a significant remodeling process. Importantly, in congenial lung 709 
lesions and COPD, there was a re-emergence of the mesenchymal fraction. Recently, 710 
proliferation of NG2+ pericytes leading to excessive coverage of pulmonary capillaries 711 
and conversion to smooth muscle-like cells contributes, in part, to vascular remodeling 712 
found in human pulmonary arterial hypertension (48). MSCs, which derive from pericytes 713 
(10), are present in the tracheal aspirates of premature infants (11) and BALs of lung 714 
transplant recipients contributing to fibrotic obliteration of the small airways (12-14). 715 
Further, an increase recovery of mesenchymal cells in BALF is predictive of future BOS 716 
events after lung transplantation (3). The anatomical location and phenotype of the 717 
infiltrating mesenchymal cell lineage found within these fibrotic lesions was not reported 718 
(32, 56). Therefore, we hypothesize that the diminished regenerative capability of fully 719 
mature adult human lung may relate to an insufficient and/or impaired functioning 720 
mesenchymal compartment. Whether this entails CD90+PDGFR+CD146+ pericyte-like 721 
cells, which are highly enriched in both early postnatal, congenital lung lesions and 722 
COPD, remains to be determined. Therefore, future studies aimed at uncovering novel 723 
cellular and molecular targets within the mesenchymal compartment in chronic lung 724 
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disorders will rely on the availability and use of human lung tissue with refined 3D 725 
models and advanced next generation sequencing technologies (47).  726 
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Pathology Notes IF H&E FC/FACS 
PL002 143 CPAM  Left lower 
lobe 
  Yes 




EpCAM/CD73  Yes 





EpCAM/CD90/PDGFRα, Yes Yes 




  Yes 
PL006 11 CPAM Upper right 
lobe 
EpCAM/CD73  Yes 
PL007 7 CPAM    Yes 











PL009 5 CPAM Right lower 
lobe 
  Yes 




  Yes 
PL012 1.5 Lobar 
emphysema 
Left lobe EpCAM/CD90/PDGFRα, 
EpCAM/CD73 
Yes Yes 





















  Yes 
PL017 192 EBV-associated 
smooth-
muscular tumor  
Left lower 
lobe 
  Yes 
PL018 181 Aspergilloma  Right lower 
lobe 
  Yes 





PL020 6 CPAM Right upper 
lobe 
  Yes 
PL021 6 CPAM Left Upper 
Lobe 
  Yes 
PL022 7 CPAM Right upper 
lobe 
  Yes 
m, months; CPAM, congenital pulmonary airway malformation; RSV, respiratory syncytial virus 745 
*same patient; FC, flow cytometry 746 
 747 
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Figure Legends 748 
Figure 1. Flow cytometric analysis of human postnatal lung identifying 749 
mesenchymal cell subsets. (A). Graphical overview of the strategy used to identify and 750 
characterize mesenchymal cell subsets in human lung. (B) Representative bivariate flow 751 
plots showing prominent mesenchymal fraction marked by EpCAM-CD45-CD31-CD14- in 752 
gate R4 (orange) in microscopically normal postnatal human lung. (C) Scatter plots 753 
showing % of EpCAM- compared with EpCAM+ fraction in postnatal lung. (D) Spearman 754 
correlation showing mesenchymal fraction decrease with age. (E) Scatter plots 755 
comparing EpCAM- cells in postnatal with adult human lung. (F) Scatter plots showing % 756 
EpCAM- and EpCAM+ cells in adult human lung. (G) Representative bivariate plot of 757 
mesenchymal EpCAM- fraction (gate R4) after subgating for the mesenchymal markers 758 
CD73 and CD90. (H) Scatter plots showing distribution of mesenchymal cell subsets. 759 
Spearman correlation showing the change in CD90+CD73- subset (I) and CD90+CD73+ 760 
subset (J) in postnatal human lung with age. (K) Representative H&E image of postnatal 761 
lung section showing microscopically normal alveolar region. (L) Immunofluorescence 762 
(IF) staining demonstrating that CD90+ (yellow arrowhead) and CD73+ cells (yellow 763 
arrow) are expressed by a subset of cells in the alveolar region in close proximity to 764 
epithelial progenitor cells marked by EpCAM (green, white arrowhead). Scale bar 50 765 
µm. n = 19, biological replicates for postnatal lung; n = 15, biological replicates for adult 766 
lung. Data are mean ± SD. Error bars show SD. Student t-test was used for comparison 767 
of paired or unpaired parametric data. All tests were two-tailed. Analysis of means for 768 
more than two groups by one-way ANOVA and multiple comparisons using post hoc 769 
Newman-Keuls test. *p < 0.05 were considered significant.  770 
 771 
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Figure 2. CD90+ identifies heterogeneous population of mesenchymal cells in 772 
early postnatal human lung. (A-B) Schematic showing strategy for expansion of 773 
FACS-sorted mesenchymal cell subsets (A) and phase contrast images showing 774 
morphology in culture (B). Scale bar 50 µm (C) Representative images of Oil Red O 775 
stain after 21 days of adipogenic differentiation. mRNA expression levels of key genes 776 
involved in adipogenesis are shown below. Scale bar 50 µm (D) Representative image 777 
of Alizarin Red S stain after 21 days in osteogenic induction media. mRNA expression 778 
levels of key genes involved in osteogenesis are shown below. Relative expression to 779 
adult BM-MSCs. n = 3-4, biological replicates. Scale bar 2000 µm (E-F) Representative 780 
image of micromass pellet cultures generated from adipose or bone marrow-derived 781 
MSCs (E) and postnatal lung-derived CD90+ subsets (F) after 21 days in chondrogenic 782 
induction media stained with Toluidine blue. Scale bar 200 µm. Data are mean ± SD. 783 
Error bars show SD. Analysis of means for more than two groups by one-way ANOVA 784 
and multiple comparisons using post hoc Newman-Keuls test. *p<0.05 were considered 785 
significant.  786 
 787 
Figure 3. CD90+ mesenchymal cells support formation of lung organoids with 788 
immature cystic-like epithelium and expand in congenital lung lesions. (A) 789 
Schematic illustration showing experimental setup to generate alveolar organoids. (B) 790 
Representative immunofluorescence image of alveolar organoids reveals epithelial 791 
saccule-like structures positive for E-cadherin (green) surrounded by PDGFRα+ 792 
mesenchymal cells (3D surface, top, xy plane). Magnified boxed region (a) of a Z stack 793 
from an individual organoid shows saccule-like features, multicellular organization and 794 
lumen formation. Scale bars: 100 µm and 30 µm. (C) IF staining of the unaffected 795 
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postnatal human lung showing a subset of CD90 cells that also co-express PDGFRα 796 
(yellow arrow) in close proximity to EpCAM+ cells (white arrowhead). Inset panel shows 797 
an enlarged view of the highlighted area (white rectangle) showing a cluster of CD90+ 798 
cells (red) and EpCAM+ cells (green). Scale bar 50 µm. (D) Relative mRNA levels in 799 
organoids from 3D coculture with autologous CD90+ mesenchymal cells compared to 2D 800 
culture conditions and postnatal lung tissue. mRNA level in postnatal lung tissue is set at 801 
one. n = 3-4, biological replicates. (E, H, K) Histological analysis of CPAM with chronic 802 
infection (E), CPAM with RSV infection (H) and chronic bronchiolitis (K). IF staining of 803 
lung sections showing EpCAM (green), CD90 (red) and PDGFRα (white) cells in CPAM 804 
with chronic infection (F-G), CPAM with RSV infection (I-J) chronic bronchiolitis (L-M). 805 
Boxed areas are magnified in right panels (F, I, L) and channels are separated without 806 
DAPI to highlight co-stained regions. Thickened interstitial spaces and dysplastic 807 
alveolar epithelium filled with CD90+ (yellow arrow) and CD90+PDGFRα+ cells (yellow 808 
arrowhead). Alv, alveolar region. Scale bar 200 µm (E, F, H), 100 µm (I, K, L), 50 µm (G, 809 
J, M). Values are presented as mean ± SD. Error bars show SD. Analysis by one-way 810 
ANOVA and multiple comparisons using post hoc Newman-Keuls. *p<0.05. ND, not 811 
detected.  812 
 813 
Figure 4. Presence of CD90+CD146+ mesenchymal cell subset that can be targeted 814 
by virosomes and live influenza A virus. (A) Representative bivariate plots showing 815 
expression of pericyte markers CD146 and NOTCH3 in CD90+CD73- and CD90+CD73- 816 
cells in postnatal human lung. (B) Scatter plots showing expression of CD146, as a % of 817 
total counted events (n = 6, biological replicates). (C) Representative flow cytometric 818 
density plots showing expression for common mesenchymal markers found to be 819 
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expressed on pericytes and fibroblasts in prospectively isolated CD90+CD73- lacking 820 
CD146 (red, top panels) and a subset expressing CD146 (blue, bottom panels) (n = 3 - 821 
5, biological replicates). (D) CD90+CD146+ mesenchymal cells exposed to virosomes or 822 
liposomes for 24h. Representative histogram plots show uptake of virosomes or 823 
liposomes by measuring Atto647 fluorescence signal by flow cytometry. (E) Scatter plots 824 
showing the change in Atto647 fluorescent signal (gMFI). (F) Representative FACS plots 825 
showing infection of postnatal CD90+CD146+ mesenchymal cells with live H1N1 826 
influenza virus (PR8 strain) after 24h compared to mock infection. (G) Representative 827 
FACS plots showing baseline fluorescence in unstained CD90+CD146+ mesenchymal 828 
cells (left plot) or isotype control for influenza nuclear protein. (H) Scatter plots showing 829 
% of CD90+CD146+ mesenchymal cells infected with live H1N1 over 48 hours. n = 3, 830 
biological replicates. (I) Scatter plots showing infectious titer of live virus shed in the 831 
culture supernatants. n = 3, biological replicates. Data are presented as mean ± SD. 832 
Error bars show SD. Student t-test was used for comparison of paired data. All tests 833 
were two-tailed. *p<0.05 were considered significant. 834 
 835 
Figure 5. Characterization of CD90+CD146+ mesenchymal cells from chronic 836 
obstructive pulmonary disease (COPD) patients. (A) Representative bivariate FACS 837 
plot showing a prominent EpCAM- mesenchymal fraction (gate R4, orange) subgated 838 
from single, live cells from a COPD patient. (B-C) Scatter plots showing percentage of 839 
EpCAM- cells (B), and EpCAM-/EpCAM+ ratio (C) in COPD (n = 15, biological replicates) 840 
(●) and non-COPD (n = 15, biological replicates) (■) lung tissue. (D) Scatter plots 841 
showing distribution of mesenchymal cell subsets. (E) Scatter plots showing CD146 is 842 
expressed in CD90+CD73- and CD90+CD73- mesenchymal cells in non-COPD 843 
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compared with COPD tissue (n = 6, non-COPD and n = 11, COPD). (F) Phase contrast 844 
image showing morphology of CD90+CD146+ mesenchymal cells from COPD compared 845 
with postnatal lung. Scale bar 50 µm. (G) mRNA expression of selected genes of 846 
various mesenchymal markers and functional categories specific to the lung in 847 
CD90+CD146+ mesenchymal cells from microscopically normal postnatal human lung (n 848 
= 4, biological replicates) and COPD patients (n = 4, biological replicates). Human lung 849 
fibroblast was set at one (not shown). (H) mRNA expression of selected genes in 850 
CD90+CD146+ mesenchymal cells from COPD (n =4) compared with postnatal human 851 
lung (n = 4, biological replicates) treated with TGFβ1 (5ng/ml) over 72 hours with or 852 
without metformin (0.5mM). Human lung fibroblasts was set at one. Values are 853 
presented as mean ± SD. Error bars show SD. Analysis by one-way ANOVA and 854 
multiple comparisons using post hoc Newman-Keuls. *p<0.05. ND, not detected. 855 
 856 
Figure 6. CD90+CD146+ cells from COPD patients fail to support microvessel 857 
formation. (A) Microfluidic chip of in vitro perfusable microvasculature network. (B) 858 
Schematic overview of chip seeding process. Microvessel characterization on day 7 for 859 
postnatal (C) and adult COPD (D) CD90+CD146+ cells stained with CD31 (red) and 860 
shown as a circular image of central chamber. Scale bar 250 µm (E, F) Series of 861 
rectangular images from a part of the central chamber stained for different marker for 862 
postnatal (E) and adult COPD (F). Scale bar 100 µm. Orthogonal view of the overlay of 863 
the images showing open lumens (white asterisk) in postnatal (G) and adult COPD (H). 864 
Scale bar 100 µm. (I) Representative images showing addition of 70 kDa RITC-dextran 865 
and perfusion of 3D microvasculature network (white arrows) formed with postnatal 866 
CD90+CD146+ cells (left panels) and lack of perfusion in COPD (right panels). Images 867 
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represent a segment of the central chamber and are overlays of the red channel and 868 
bright field at specific time points. Scale bar 200 µm. (J, K) IF staining shows CD31+ 869 
(red) microvessel-like structure after 7 days in the presence of antifibrinolytic agent ε-870 
Aminocaproic acid (EACA, 200 µg/ml) for postnatal (J) and COPD (K) CD90+CD146+ 871 
cells cultured with HUVECs. Scale bar 250 µm. (L, M) Schematic highlighting 3D 872 
microvasculature structure in the central chamber with orthogonal view of the overlay 873 
from serial images showing open lumens in postnatal (L) and in COPD (M). Scale bar 874 
100 µm. (N) Representative image showing RITC-dextran perfusion of 3D 875 
microvasculature network in the presence of EACA for postnatal left panels) and COPD 876 
(right panels) microvasculature structures. Scale bar 200 µm. (O) Bar graph showing 877 
quantification of vessel diameter. n = 4, biological replicates. Data presented as mean ± 878 
SD. Student t-test was used for comparison of unpaired parametric data. All tests were 879 
two-tailed. *p<0.05 were considered significant.  880 
  881 




1. Ahlbrecht K, and McGowan SE. In search of the elusive lipofibroblast in human lungs. American 883 
journal of physiology Lung cellular and molecular physiology 307: L605-608, 2014. 884 
2. Astarita JL, Acton SE, and Turley SJ. Podoplanin: emerging functions in development, the 885 
immune system, and cancer. Frontiers in immunology 3: 283, 2012. 886 
3. Badri L, Murray S, Liu LX, Walker NM, Flint A, Wadhwa A, Chan KM, Toews GB, Pinsky DJ, 887 
Martinez FJ, and Lama VN. Mesenchymal stromal cells in bronchoalveolar lavage as predictors of 888 
bronchiolitis obliterans syndrome. American journal of respiratory and critical care medicine 183: 1062-889 
1070, 2011. 890 
4. Barkauskas CE, Cronce MJ, Rackley CR, Bowie EJ, Keene DR, Stripp BR, Randell SH, Noble PW, 891 
and Hogan BL. Type 2 alveolar cells are stem cells in adult lung. The Journal of clinical investigation 123: 892 
3025-3036, 2013. 893 
5. Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. 894 
Nature reviews Immunology 2018. 895 
6. Barron L, Gharib SA, and Duffield JS. Lung Pericytes and Resident Fibroblasts: Busy Multitaskers. 896 
The American journal of pathology 186: 2519-2531, 2016. 897 
7. Beers MF, and Morrisey EE. The three R's of lung health and disease: repair, remodeling, and 898 
regeneration. The Journal of clinical investigation 121: 2065-2073, 2011. 899 
8. Bichsel CA, Wang L, Froment L, Berezowska S, Muller S, Dorn P, Marti TM, Peng RW, Geiser T, 900 
Schmid RA, Guenat OT, and Hall SRR. Increased PD-L1 expression and IL-6 secretion characterize human 901 
lung tumor-derived perivascular-like cells that promote vascular leakage in a perfusable 902 
microvasculature model. Scientific reports 7: 10636, 2017. 903 
9. Blom RA, Erni ST, Krempaska K, Schaerer O, van Dijk RM, Amacker M, Moser C, Hall SR, von 904 
Garnier C, and Blank F. A Triple Co-Culture Model of the Human Respiratory Tract to Study Immune-905 
Modulatory Effects of Liposomes and Virosomes. PloS one 11: e0163539, 2016. 906 
10. Bozyk PD, Popova AP, Bentley JK, Goldsmith AM, Linn MJ, Weiss DJ, and Hershenson MB. 907 
Mesenchymal stromal cells from neonatal tracheal aspirates demonstrate a pattern of lung-specific gene 908 
expression. Stem cells and development 20: 1995-2007, 2011. 909 
11. Collins JJP, Lithopoulos MA, Dos Santos CC, Issa N, Mobius MA, Ito C, Zhong S, Vadivel A, and 910 
Thebaud B. Impaired Angiogenic Supportive Capacity and Altered Gene Expression Profile of Resident 911 
CD146(+) Mesenchymal Stromal Cells Isolated from Hyperoxia-Injured Neonatal Rat Lungs. Stem cells 912 
and development 27: 1109-1124, 2018. 913 
12. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, 914 
Norotte C, Teng PN, Traas J, Schugar R, Deasy BM, Badylak S, Buhring HJ, Giacobino JP, Lazzari L, Huard 915 
J, and Peault B. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem 916 
Cell 3: 301-313, 2008. 917 
13. Crystal RG. Airway basal cells. The "smoking gun" of chronic obstructive pulmonary disease. 918 
American journal of respiratory and critical care medicine 190: 1355-1362, 2014. 919 
14. Duong H, Wu B, and Tawil B. Modulation of 3D fibrin matrix stiffness by intrinsic fibrinogen-920 
thrombin compositions and by extrinsic cellular activity. Tissue engineering Part A 15: 1865-1876, 2009. 921 
15. Durell J, Thakkar H, Gould S, Fowler D, and Lakhoo K. Pathology of asymptomatic, prenatally 922 
diagnosed cystic lung malformations. J Pediatr Surg 51: 231-235, 2016. 923 
16. El Agha E, Herold S, Al Alam D, Quantius J, MacKenzie B, Carraro G, Moiseenko A, Chao CM, 924 
Minoo P, Seeger W, and Bellusci S. Fgf10-positive cells represent a progenitor cell population during 925 
lung development and postnatally. Development 141: 296-306, 2014. 926 
17. El Agha E, Moiseenko A, Kheirollahi V, De Langhe S, Crnkovic S, Kwapiszewska G, Szibor M, 927 
Kosanovic D, Schwind F, Schermuly RT, Henneke I, MacKenzie B, Quantius J, Herold S, Ntokou A, 928 
Ahlbrecht K, Braun T, Morty RE, Gunther A, Seeger W, and Bellusci S. Two-Way Conversion between 929 
Downloaded from journals.physiology.org/journal/ajplung at Hauptbibliothek Univ Zurich (144.200.017.040) on March 18, 2020.
41 
 
Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. 930 
Cell Stem Cell 20: 571, 2017. 931 
18. Engler AJ, Sen S, Sweeney HL, and Discher DE. Matrix elasticity directs stem cell lineage 932 
specification. Cell 126: 677-689, 2006. 933 
19. Geiger S, Hirsch D, and Hermann FG. Cell therapy for lung disease. European respiratory review : 934 
an official journal of the European Respiratory Society 26: 2017. 935 
20. Ghosh M, Miller YE, Nakachi I, Kwon JB, Baron AE, Brantley AE, Merrick DT, Franklin WA, Keith 936 
RL, and Vandivier RW. Exhaustion of Airway Basal Progenitor Cells in Early and Established Chronic 937 
Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine 197: 885-896, 938 
2018. 939 
21. Glassberg MK, Minkiewicz J, Toonkel RL, Simonet ES, Rubio GA, DiFede D, Shafazand S, Khan A, 940 
Pujol MV, LaRussa VF, Lancaster LH, Rosen GD, Fishman J, Mageto YN, Mendizabal A, and Hare JM. 941 
Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via 942 
Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial. Chest 151: 971-981, 2017. 943 
22. Greenbaum A, Hsu YM, Day RB, Schuettpelz LG, Christopher MJ, Borgerding JN, Nagasawa T, 944 
and Link DC. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell 945 
maintenance. Nature 495: 227-230, 2013. 946 
23. Hall SR, Jiang Y, Leary E, Yavanian G, Eminli S, O'Neill DW, and Marasco WA. Identification and 947 
isolation of small CD44-negative mesenchymal stem/progenitor cells from human bone marrow using 948 
elutriation and polychromatic flow cytometry. Stem Cells Transl Med 2: 567-578, 2013. 949 
24. Heinzelmann K, Lehmann M, Gerckens M, Noskovicova N, Frankenberger M, Lindner M, Hatz 950 
R, Behr J, Hilgendorff A, Konigshoff M, and Eickelberg O. Cell-surface phenotyping identifies CD36 and 951 
CD97 as novel markers of fibroblast quiescence in lung fibrosis. American journal of physiology Lung 952 
cellular and molecular physiology 315: L682-L696, 2018. 953 
25. Herzenberg LA, Tung J, Moore WA, Herzenberg LA, and Parks DR. Interpreting flow cytometry 954 
data: a guide for the perplexed. Nature immunology 7: 681-685, 2006. 955 
26. Hung CF, Mittelsteadt KL, Brauer R, McKinney BL, Hallstrand TS, Parks WC, Chen P, Schnapp 956 
LM, Liles WC, Duffield JS, and Altemeier WA. Lung pericyte-like cells are functional interstitial immune 957 
sentinel cells. American journal of physiology Lung cellular and molecular physiology 312: L556-L567, 958 
2017. 959 
27. Kheirollahi V, Wasnick RM, Biasin V, Vazquez-Armendariz AI, Chu X, Moiseenko A, Weiss A, 960 
Wilhelm J, Zhang JS, Kwapiszewska G, Herold S, Schermuly RT, Mari B, Li X, Seeger W, Gunther A, 961 
Bellusci S, and El Agha E. Metformin induces lipogenic differentiation in myofibroblasts to reverse lung 962 
fibrosis. Nature communications 10: 2987, 2019. 963 
28. Kotton DN, and Morrisey EE. Lung regeneration: mechanisms, applications and emerging stem 964 
cell populations. Nature medicine 20: 822-832, 2014. 965 
29. Kramann R, Schneider RK, DiRocco DP, Machado F, Fleig S, Bondzie PA, Henderson JM, Ebert 966 
BL, and Humphreys BD. Perivascular Gli1+ progenitors are key contributors to injury-induced organ 967 
fibrosis. Cell Stem Cell 16: 51-66, 2015. 968 
30. Kranenburg AR, de Boer WI, Alagappan VK, Sterk PJ, and Sharma HS. Enhanced bronchial 969 
expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic 970 
obstructive pulmonary disease. Thorax 60: 106-113, 2005. 971 
31. Kratzer A, Chu HW, Salys J, Moumen Z, Leberl M, Bowler R, Cool C, Zamora M, and 972 
Taraseviciene-Stewart L. Endothelial cell adhesion molecule CD146: implications for its role in the 973 
pathogenesis of COPD. The Journal of pathology 230: 388-398, 2013. 974 
32. Lama VN, Smith L, Badri L, Flint A, Andrei AC, Murray S, Wang Z, Liao H, Toews GB, Krebsbach 975 
PH, Peters-Golden M, Pinsky DJ, Martinez FJ, and Thannickal VJ. Evidence for tissue-resident 976 
mesenchymal stem cells in human adult lung from studies of transplanted allografts. The Journal of 977 
clinical investigation 117: 989-996, 2007. 978 
Downloaded from journals.physiology.org/journal/ajplung at Hauptbibliothek Univ Zurich (144.200.017.040) on March 18, 2020.
42 
 
33. Lemos DR, and Duffield JS. Tissue-resident mesenchymal stromal cells: Implications for tissue-979 
specific antifibrotic therapies. Science translational medicine 10: 2018. 980 
34. Lignelli E, Palumbo F, Myti D, and Morty RE. Recent advances in our understanding of the 981 
mechanisms of lung alveolarization and bronchopulmonary dysplasia. American journal of physiology 982 
Lung cellular and molecular physiology 317: L832-L887, 2019. 983 
35. Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM, Newby DE, and Macnee 984 
W. Vascular dysfunction in chronic obstructive pulmonary disease. American journal of respiratory and 985 
critical care medicine 180: 513-520, 2009. 986 
36. Mendes ES, Campos MA, and Wanner A. Airway blood flow reactivity in healthy smokers and in 987 
ex-smokers with or without COPD. Chest 129: 893-898, 2006. 988 
37. Mercer PF, Woodcock HV, Eley JD, Plate M, Sulikowski MG, Durrenberger PF, Franklin L, 989 
Nanthakumar CB, Man Y, Genovese F, McAnulty RJ, Yang S, Maher TM, Nicholson AG, Blanchard AD, 990 
Marshall RP, Lukey PT, and Chambers RC. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel 991 
anti-fibrotic agent in IPF. Thorax 71: 701-711, 2016. 992 
38. Mobius MA, Freund D, Vadivel A, Koss S, McConaghy S, Ohls RK, Rudiger M, and Thebaud B. 993 
Oxygen Disrupts Human Fetal Lung Mesenchymal Cells. Implications for Bronchopulmonary Dysplasia. 994 
American journal of respiratory cell and molecular biology 60: 592-600, 2019. 995 
39. Nabhan AN, Brownfield DG, Harbury PB, Krasnow MA, and Desai TJ. Single-cell Wnt signaling 996 
niches maintain stemness of alveolar type 2 cells. Science 359: 1118-1123, 2018. 997 
40. Park J, Ivey MJ, Deana Y, Riggsbee KL, Sorensen E, Schwabl V, Sjoberg C, Hjertberg T, Park GY, 998 
Swonger JM, Rosengreen T, Morty RE, Ahlbrecht K, and Tallquist MD. The Tcf21 lineage constitutes the 999 
lung lipofibroblast population. American journal of physiology Lung cellular and molecular physiology 1000 
316: L872-L885, 2019. 1001 
41. Parks DR, Roederer M, and Moore WA. A new "Logicle" display method avoids deceptive effects 1002 
of logarithmic scaling for low signals and compensated data. Cytometry A 69: 541-551, 2006. 1003 
42. Pogoriler J, Swarr D, Kreiger P, Adzick NS, and Peranteau W. Congenital Cystic Lung Lesions: 1004 
Redefining the Natural Distribution of Subtypes and Assessing the Risk of Malignancy. The American 1005 
journal of surgical pathology 43: 47-55, 2019. 1006 
43. Popova AP, Bentley JK, Cui TX, Richardson MN, Linn MJ, Lei J, Chen Q, Goldsmith AM, Pryhuber 1007 
GS, and Hershenson MB. Reduced platelet-derived growth factor receptor expression is a primary 1008 
feature of human bronchopulmonary dysplasia. American journal of physiology Lung cellular and 1009 
molecular physiology 307: L231-239, 2014. 1010 
44. Popova AP, Bozyk PD, Bentley JK, Linn MJ, Goldsmith AM, Schumacher RE, Weiner GM, Filbrun 1011 
AG, and Hershenson MB. Isolation of tracheal aspirate mesenchymal stromal cells predicts 1012 
bronchopulmonary dysplasia. Pediatrics 126: e1127-1133, 2010. 1013 
45. Rafii S, Cao Z, Lis R, Siempos, II, Chavez D, Shido K, Rabbany SY, and Ding BS. Platelet-derived 1014 
SDF-1 primes the pulmonary capillary vascular niche to drive lung alveolar regeneration. Nat Cell Biol 17: 1015 
123-136, 2015. 1016 
46. Reicherzer T, Haffner S, Shahzad T, Gronbach J, Mysliwietz J, Hubener C, Hasbargen U, 1017 
Gertheiss J, Schulze A, Bellusci S, Morty RE, Hilgendorff A, and Ehrhardt H. Activation of the NF-kappaB 1018 
pathway alters the phenotype of MSCs in the tracheal aspirates of preterm infants with severe BPD. 1019 
American journal of physiology Lung cellular and molecular physiology 315: L87-L101, 2018. 1020 
47. Reyfman PA, Walter JM, Joshi N, Anekalla KR, McQuattie-Pimentel AC, Chiu S, Fernandez R, 1021 
Akbarpour M, Chen CI, Ren Z, Verma R, Abdala-Valencia H, Nam K, Chi M, Han S, Gonzalez-Gonzalez FJ, 1022 
Soberanes S, Watanabe S, Williams KJN, Flozak AS, Nicholson TT, Morgan VK, Winter DR, Hinchcliff M, 1023 
Hrusch CL, Guzy RD, Bonham CA, Sperling AI, Bag R, Hamanaka RB, Mutlu GM, Yeldandi AV, Marshall 1024 
SA, Shilatifard A, Amaral LAN, Perlman H, Sznajder JI, Argento AC, Gillespie CT, Dematte J, Jain M, 1025 
Singer BD, Ridge KM, Lam AP, Bharat A, Bhorade SM, Gottardi CJ, Budinger GRS, and Misharin AV. 1026 
Downloaded from journals.physiology.org/journal/ajplung at Hauptbibliothek Univ Zurich (144.200.017.040) on March 18, 2020.
43 
 
Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary 1027 
Fibrosis. American journal of respiratory and critical care medicine 2018. 1028 
48. Ricard N, Tu L, Le Hiress M, Huertas A, Phan C, Thuillet R, Sattler C, Fadel E, Seferian A, 1029 
Montani D, Dorfmuller P, Humbert M, and Guignabert C. Increased pericyte coverage mediated by 1030 
endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in 1031 
pulmonary hypertension. Circulation 129: 1586-1597, 2014. 1032 
49. Smith LR, Cho S, and Discher DE. Stem Cell Differentiation is Regulated by Extracellular Matrix 1033 
Mechanics. Physiology 33: 16-25, 2018. 1034 
50. Staudt MR, Buro-Auriemma LJ, Walters MS, Salit J, Vincent T, Shaykhiev R, Mezey JG, Tilley AE, 1035 
Kaner RJ, Ho MW, and Crystal RG. Airway Basal stem/progenitor cells have diminished capacity to 1036 
regenerate airway epithelium in chronic obstructive pulmonary disease. American journal of respiratory 1037 
and critical care medicine 190: 955-958, 2014. 1038 
51. Swarr DT, Peranteau WH, Pogoriler J, Frank DB, Adzick NS, Hedrick HL, Morley M, Zhou S, and 1039 
Morrisey EE. Novel Molecular and Phenotypic Insights into Congenital Lung Malformations. American 1040 
journal of respiratory and critical care medicine 2018. 1041 
52. Tahedl D, Wirkes A, Tschanz SA, Ochs M, and Muhlfeld C. How common is the lipid body-1042 
containing interstitial cell in the mammalian lung? American journal of physiology Lung cellular and 1043 
molecular physiology 307: L386-394, 2014. 1044 
53. Tamura S, Suzuki-Inoue K, Tsukiji N, Shirai T, Sasaki T, Osada M, Satoh K, and Ozaki Y. 1045 
Podoplanin-positive periarteriolar stromal cells promote megakaryocyte growth and proplatelet 1046 
formation in mice by CLEC-2. Blood 127: 1701-1710, 2016. 1047 
54. Tata PR, and Rajagopal J. Plasticity in the lung: making and breaking cell identity. Development 1048 
144: 755-766, 2017. 1049 
55. Togo S, Holz O, Liu X, Sugiura H, Kamio K, Wang X, Kawasaki S, Ahn Y, Fredriksson K, Skold CM, 1050 
Mueller KC, Branscheid D, Welker L, Watz H, Magnussen H, and Rennard SI. Lung fibroblast repair 1051 
functions in patients with chronic obstructive pulmonary disease are altered by multiple mechanisms. 1052 
American journal of respiratory and critical care medicine 178: 248-260, 2008. 1053 
56. Walker N, Badri L, Wettlaufer S, Flint A, Sajjan U, Krebsbach PH, Keshamouni VG, Peters-1054 
Golden M, and Lama VN. Resident tissue-specific mesenchymal progenitor cells contribute to 1055 
fibrogenesis in human lung allografts. The American journal of pathology 178: 2461-2469, 2011. 1056 
57. Weibel ER. On pericytes, particularly their existence on lung capillaries. Microvascular research 1057 
8: 218-235, 1974. 1058 
58. Wilson CL, Stephenson SE, Higuero JP, Feghali-Bostwick C, Hung CF, and Schnapp LM. 1059 
Characterization of human PDGFR-beta-positive pericytes from IPF and non-IPF lungs. American journal 1060 
of physiology Lung cellular and molecular physiology 315: L991-L1002, 2018. 1061 
59. Xi Y, Kim T, Brumwell AN, Driver IH, Wei Y, Tan V, Jackson JR, Xu J, Lee DK, Gotts JE, Matthay 1062 
MA, Shannon JM, Chapman HA, and Vaughan AE. Local lung hypoxia determines epithelial fate 1063 
decisions during alveolar regeneration. Nat Cell Biol 19: 904-914, 2017. 1064 
60. Xie T, Wang Y, Deng N, Huang G, Taghavifar F, Geng Y, Liu N, Kulur V, Yao C, Chen P, Liu Z, 1065 
Stripp B, Tang J, Liang J, Noble PW, and Jiang D. Single-Cell Deconvolution of Fibroblast Heterogeneity in 1066 
Mouse Pulmonary Fibrosis. Cell reports 22: 3625-3640, 2018. 1067 
61. Zeinali S, Bichsel CA, Hobi N, Funke M, Marti TM, Schmid RA, Guenat OT, and Geiser T. Human 1068 
microvasculature-on-a chip: anti-neovasculogenic effect of nintedanib in vitro. Angiogenesis 21: 861-871, 1069 
2018. 1070 
62. Zepp JA, Zacharias WJ, Frank DB, Cavanaugh CA, Zhou S, Morley MP, and Morrisey EE. Distinct 1071 
Mesenchymal Lineages and Niches Promote Epithelial Self-Renewal and Myofibrogenesis in the Lung. 1072 
Cell 170: 1134-1148 e1110, 2017. 1073 
 1074 
Downloaded from journals.physiology.org/journal/ajplung at Hauptbibliothek Univ Zurich (144.200.017.040) on March 18, 2020.
Downloaded from journals.physiology.org/journal/ajplung at Hauptbibliothek Univ Zurich (144.200.017.040) on March 18, 2020.
Downloaded from journals.physiology.org/journal/ajplung at Hauptbibliothek Univ Zurich (144.200.017.040) on March 18, 2020.
Downloaded from journals.physiology.org/journal/ajplung at Hauptbibliothek Univ Zurich (144.200.017.040) on March 18, 2020.
Downloaded from journals.physiology.org/journal/ajplung at Hauptbibliothek Univ Zurich (144.200.017.040) on March 18, 2020.
Downloaded from journals.physiology.org/journal/ajplung at Hauptbibliothek Univ Zurich (144.200.017.040) on March 18, 2020.
Downloaded from journals.physiology.org/journal/ajplung at Hauptbibliothek Univ Zurich (144.200.017.040) on March 18, 2020.
